"Therapeutic Monoclonal Antibodies: World Market 2010-2025", published by Visiongain Ltd.

Oct. 8, 2010 - PRLog -- Report Details
– our report shows you the technological and commercial opportunities there

In 2009, the therapeutic monoclonal antibodies market generated total revenues of over $35bn worldwide. From 2010 onwards, this sector will benefit from new drugs and expanding indications for existing products, our latest study shows. New technologies will be an important driver of revenue growth. Intensive R&D activity is producing a strong R&D pipeline, filled with novel monoclonal antibodies, antibody fragments and antibody-drug conjugates. We expect significant opportunities for further commercial growth, as discussed in our latest report.

Therapeutic Monoclonal Antibodies: World Market 2010-2025 explains how this market will develop, and where the commercial opportunities will lie. There remain high revenues to be made in this sector from 2010 to 2025. Our report explains where, why and by whom. What will be the characteristics of drugs that will succeed Avastin and Remicade? Will they become the blockbusters of the future? What are the potential applications and prospects for antibody fragments? Which R&D pipeline agents have most commercial promise? Our report will show you the outlook for this dynamic sector, providing information that will benefit your work, saving you time and aiding your decision making.

Our report covers the following products in detail:
• Avastin
• Herceptin
• MabThera
• Erbitux
• Remicade
• Humira
• Tysabri
• Synagis
• Lucentis
• Xolair.

What monoclonal antibodies are likely to enter the market from 2010 onwards, and will they dominate? How will patent expiry and biosimilar products influence the market? Where will the main opportunities lie, and what are the drivers and restraints in this industry and market? Our report will provide you with the information that you need to understand current trends and future directions in the market for therapeutic monoclonal antibodies.

Comprehensive analysis of the industry and market for therapeutic mAbs

Therapeutic Monoclonal Antibodies: World Market 2010-2025 examines that sector through a comprehensive review of information sources. We harness primary and secondary research. This report provides sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 80 tables and figures included, as well as three interviews with experts. The result is a market- and industry-centred study, with detailed analyses and opinion to benefit your work.

Why you should buy Therapeutic Monoclonal Antibodies: World Market 2010-2025

Our report gives you the following benefits in particular:
• You will assess the current market for therapeutic monoclonal antibodies, as well as recent trends there
• You will review the overall market area from 2010 to 2025, including global sales forecasts
• You will receive forecasts for the main subgroups of the therapeutic mAbs market, showing you where opportunities for revenue growth will occur from 2010 onwards
• You will receive sales forecasts for the leading products in this market from 2010 to 2025, with discussions of market potential and competition
• You will receive sales forecasts for leading geographical markets from 2010 to 2025, with discussions and other supporting information
• You will analyse the drivers, restraints, competition and opportunities influencing the market for therapeutic monoclonal antibodies from 2010 onwards
• You will investigate under-met needs, with therapeutic requirements and commercial opportunities covered
• You will discover the most exciting R&D pipeline developments in the sector
• You will receive expert views on the sector, including full interview transcripts.

You can obtain this report today

Our new report is essential reading for everybody interested in the expanding market for therapeutic monoclonal antibodies. This report provides an analysis of the world market, giving a balanced view of technological and commercial prospects there. Do you want to know more about this important market and harness its opportunities? You can stay ahead by ordering our report today.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Conatact Person:

Bijal Patel
bijal.patel@visiongainglobal.com
0044(0)20 7549 9946

# # #

Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services.